Cargando…
Treatment selection for patients with relapsed or refractory follicular lymphoma
Follicular lymphoma (FL) is the second most common lymphoma in the United States and is characterized by a variable clinical course, disease heterogeneity, and a relapse-and-remittance pattern historically accompanied by successive shortening of clinical response with every line of treatment. Factor...
Autores principales: | Skarbnik, Alan Z., Patel, Krish |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10028236/ https://www.ncbi.nlm.nih.gov/pubmed/36959808 http://dx.doi.org/10.3389/fonc.2023.1120358 |
Ejemplares similares
-
The role of tazemetostat in relapsed/refractory follicular lymphoma
por: von Keudell, Gottfried, et al.
Publicado: (2021) -
Recent Advances in the Management of Patients with Relapsed/Refractory Follicular Lymphoma
por: Pongas, Georgios, et al.
Publicado: (2021) -
Targeted Treatment of Relapsed or Refractory Follicular Lymphoma: Focus on the Therapeutic Potential of Mosunetuzumab
por: Lopedote, Paolo, et al.
Publicado: (2023) -
Peripheral T-Cell Lymphomas: A Review of Current Approaches and Hopes for the Future
por: Skarbnik, Alan P., et al.
Publicado: (2013) -
Anti-CD20–atezolizumab–polatuzumab vedotin in relapsed/refractory follicular and diffuse large B-cell lymphoma
por: Topp, Max S., et al.
Publicado: (2022)